Altamira Therapeutics Announces Collaboration With Heqet Therapeutics On Nanoparticle-Delivered Non-Coding RNAs For Cardiac Regeneration
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has announced a collaboration with Heqet Therapeutics to test nanoparticles based on Altamira's OligoPhore delivery platform for cardiac regeneration. The aim is to regenerate damaged heart tissue.
July 05, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altamira Therapeutics, listed as CYTO, is entering a collaboration with Heqet Therapeutics to test a new application of its OligoPhore delivery platform. This could potentially open up new revenue streams for the company.
The news of Altamira's collaboration with Heqet Therapeutics is directly relevant to the company and its stock. The partnership could potentially open up new revenue streams for Altamira if the application of its OligoPhore delivery platform in cardiac regeneration proves successful. This could positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100